[Melatonin modulates the expression of pulmonary prostanoids].

Area of Science:

• Neonatal physiology
• High-altitude medicine
• Pharmacology

Background:

• High-altitude living (above 2,500m) can cause pulmonary arterial hypertension of the neonate (PAHN).
• PAHN is characterized by pulmonary vessel remodeling, abnormal vascular reactivity, and oxidative stress.
• Melatonin may offer antioxidant, anti-remodeling, and vasodilating benefits for PAHN.

Purpose of the Study:

• To investigate the impact of melatonin on prostanoid pathway gene expression in the lungs of neonatal lambs.
• To assess melatonin's effects under conditions simulating high-altitude hypobaric hypoxia.

Main Methods:

• Neonatal lambs were exposed to 3,600m and treated with either melatonin or a vehicle from day 4 to 21.
• Lung tissues were analyzed post-treatment for prostanoid synthase and receptor expression using RT-PCR and Western Blot.

Main Results:

• Melatonin administration upregulated prostacyclin synthase transcript and prostacyclin receptor protein.
• The treatment downregulated both transcript and protein expression of cyclooxygenase-2 (COX-2).
• No significant changes were observed in the expression of the vasoconstrictor thromboxane pathway.

Conclusions:

• Postnatal melatonin treatment enhances the prostacyclin vasodilator pathway in high-altitude exposed lambs.
• Melatonin's reduction of COX-2 suggests potential for decreased oxidative stress and inflammation.
• Melatonin shows promise for managing high-altitude-induced pulmonary hypertension in neonates.